Ogivri is a type of monoclonal antibody and a HER2 receptor antagonist.
This means Ogivri works in two primary ways:
-
Monoclonal Antibody: As a monoclonal antibody, Ogivri is designed to specifically target a particular protein in the body.
-
HER2 Receptor Antagonist: Ogivri targets the HER2 protein (Human Epidermal Growth Factor Receptor 2), which is found in high levels on some cancer cells, particularly in certain types of breast cancer. By binding to HER2, Ogivri blocks signals that promote cancer cell growth, effectively slowing down or stopping the spread of the cancer. It may also help the immune system to kill cancer cells.
Ogivri is also being studied for the treatment of other types of cancer.
